Comparative clinical trial to evaluate the efficacy of shuddha guggulu with and without virechana karma in dyslipidemia
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Primary outcomes would be measured by lab investigation of extended lipid profile (
研究概览
简要总结
Cholesterol levels are estimated to cause 18% of the global CVDs and 56% of global ischemic heart disease (IHD). For every 1% reduction in lipid level , the risk of heart disease reduces by 2.5%. Dyslipidemia is a established risk factor for atherosclerotic disease. In india , there has been an alarming increase in the prevalence of CVD over the past two decades. In this view it is need of the hour to find a cost effective , non invasive treatment protocol to combat Dyslipidemia that May act as a preventive tactic for cardiovascular diseases.
This study is an attempt to explore the efficacy and add on effect of virechana karma in dyslipidemic patients by normalizing lipid metabolism.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 盲法
- None
入排标准
- 年龄范围
- 20.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Any one of the dearranged parameter of lipid profile ( Total cholesterol, Triglyceride, LDL, HDL, VLDL) 2) Patient of either sex of age between 20 – 65.
排除标准
- •Patients who are contraindicated for virechana karma- like lower GI bleeding, Prolapse of rectum, incontinence of stool, Pregnant and lactating women will not be included in the trial in group A.
- •CAD patients , patients on any ongoing medications that are likely to affect lipid levels.
- •Patients with renal or hepatic impairement (Sr creatinine greater than 1.8mg/dl, SGPOT greater than 200u/L, SGPT greater than 280uL).
- •Patients with co-morbid conditions such as Hypertension grade 2 ( greater than or equal to 160/100mm of Hg) or more, Diabetes Mellitus (having HbA1c greater than 7.5 percent with or without hyperglycemic medications 5) Patients who are on anti tubercular , anti retroviral and anti hyperlipidemic medications.
- •Patients requiring emergency treatment.
结局指标
主要结局
Primary outcomes would be measured by lab investigation of extended lipid profile (
时间窗: Primary outcomes would be measured by lab investigation of extended lipid profile ( | including total cholesterol, triglyceride, ldl, vldl, hdl, apolipoprotein A1 and | apolipoprotein B) | On baseline | 60 days ,i.e, after completion of trial
including total cholesterol, triglyceride, ldl, vldl, hdl, apolipoprotein A1 and
时间窗: Primary outcomes would be measured by lab investigation of extended lipid profile ( | including total cholesterol, triglyceride, ldl, vldl, hdl, apolipoprotein A1 and | apolipoprotein B) | On baseline | 60 days ,i.e, after completion of trial
apolipoprotein B)
时间窗: Primary outcomes would be measured by lab investigation of extended lipid profile ( | including total cholesterol, triglyceride, ldl, vldl, hdl, apolipoprotein A1 and | apolipoprotein B) | On baseline | 60 days ,i.e, after completion of trial
次要结局
- To asses the add on effect of virechana karma with Shuddha guggulu on Hs-CRP level.(The proportion of patients showing improvement in the quality of life using the)
研究者
Dr Manoj Shamkuwar
Ayurvedic and Unani Tibbia College and Hospital